Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Furazolidone→

Furazolidone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
67-45-8
Molecular formula
C8H7N3O5
Molecular weight
225.16 g/mol
Drug class
Nitrofuran antibacterial and antiprotozoal agentmonoamine oxidase inhibitor properties
Mechanism of action
After bacterial reduction of its nitro group, reactive intermediates damage microbial DNA and other macromolecules. It also has monoamine oxidase-inhibiting properties that can cause clinically important food and drug interactions.
Indications / reported uses
  • Historically used for selected bacterial diarrhoeal and protozoal infections, including giardiasis, cholera and dysentery in countries where authorised; use is restricted or discontinued in many jurisdictions and should not be presented as routine contemporary therapy

Sources: NLM MeSH — Furazolidone · PubMed — Furazolidone clinical use and safety · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Furazolidone Environmental Risk Assessment (ERA) (the Furazolidone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.